S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin
Open Access
- 14 June 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (3) , 817-825
Abstract
Objectives: Our previous studies have demonstrated that the Damage Associated Molecular Pattern (DAMP) protein, S100A4, is overexpressed in the involved skin and peripheral blood of patients with SSc. It is associated with skin and lung involvement, and disease activity. By contrast, lack of S100A4 prevented the development of experimental dermal fibrosis. Herein we aimed to evaluate the effect of murine anti-S100A4 mAb 6B12 in the treatment of preestablished experimental dermal fibrosis. Methods: The effects of 6B12 were assessed at therapeutic dosages in a modified bleomycin-induced dermal fibrosis mouse model by evaluating fibrotic (dermal thickness, proliferation of myofibroblasts, hydroxyproline content, phosphorylated Smad3-positive cell count) and inflammatory (leukocytes infiltrating the lesional skin, systemic levels of selected cytokines and chemokines) outcomes, and transcriptional profiling (RNA sequencing). Results: Treatment with 7.5 mg/kg 6B12 attenuated and might even reduce pre-existing dermal fibrosis induced by bleomycin as evidenced by reduction in dermal thickness, myofibroblast count and collagen content. These antifibrotic effects were mediated by the downregulation of TGF-β/Smad signalling and partially by reducing the number of leukocytes infiltrating the lesional skin and decrease in the systemic levels of IL-1α, eotaxin, CCL2 and CCL5. Moreover, transcriptional profiling demonstrated that 7.5 mg/kg 6B12 also modulated several profibrotic and proinflammatory processes relevant to the pathogenesis of SSc. Conclusion: Targeting S100A4 by the 6B12 mAb demonstrated potent antifibrotic and anti-inflammatory effects on bleomycin-induced dermal fibrosis and provided further evidence for the vital role of S100A4 in the pathophysiology of SSc.Keywords
Funding Information
- Ministry of Health of the Czech Republic (023728)
- Ministry of Education Youth and Sports
- Czech Republic (SVV 260638, DI 1537/14-1, DI 1537/17-1, DI 1537/20–1, DI 1537/22-1, DI 1537/23-1)
- German Research Foundation
- German Research Foundation (2013.056.1)
This publication has 46 references indexed in Scilit:
- Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic SclerosisJournal of Investigative Dermatology, 2013
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidenceCancer and Metastasis Reviews, 2011
- Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosisArthritis & Rheumatism, 2010
- Animal models of systemic sclerosis: Prospects and limitationsArthritis & Rheumatism, 2010
- S100A4 and MetastasisThe American Journal of Pathology, 2010
- Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosisRheumatology, 2008
- Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-AJournal of Clinical Investigation, 1999
- Sequential dermal microvascular and perivascular changes in the development of sclerodermaThe Journal of Pathology, 1992
- The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acidArchives of Biochemistry and Biophysics, 1961